MOMA Gets $150M to Make Small Molecules Against ATPases, Laborers of the Cell

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Third Rock Raises $1.1B Fund, Sticks With Its Knitting in a Downturn
Third Rock-Backed Abata Secures $95M for T-reg Cell Therapy Against MS
Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?